FRANCISCO CASQUERO OCIO-rekin lankidetzan egindako argitalpenak (28)

2022

  1. Quality of life improvement in patients with bone metastases undergoing palliative radiotherapy

    Reports of Practical Oncology and Radiotherapy, Vol. 27, Núm. 3, pp. 428-439

2021

  1. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

2020

  1. MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

    Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139

  2. Pain response and quality of life assessment in patients with moderate/severe neuropathic pain due to bone metastasis undergoing treatment with palliative radiotherapy and tapentadol: A prospective multicentre pilot study

    Journal of Medical Imaging and Radiation Oncology, Vol. 64, Núm. 6, pp. 859-865

  3. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial

    Radiotherapy and Oncology, Vol. 146, pp. 16-20

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  2. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

  3. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT

    European Journal of Cancer Care, Vol. 28, Núm. 5

2018

  1. Analysis of predictors of pain response in patients with bone metastasis undergoing palliative radiotherapy: Does age matter?

    Journal of Medical Imaging and Radiation Oncology, Vol. 62, Núm. 4, pp. 578-584

  2. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial

    Radiotherapy and Oncology, Vol. 126, Núm. 2, pp. 278-282

  3. Infrastructure and equipment for radiation oncology in the Spanish National Health System: analysis of external beam radiotherapy 2015–2020

    Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 402-410

  4. Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 101, Núm. 5, pp. 1172-1178

2017

  1. Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision

    Brachytherapy, Vol. 16, Núm. 1, pp. 201-206

2016

  1. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial

    Radiotherapy and Oncology, Vol. 119, Núm. 1, pp. 91-96

  2. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: The point of view of the radiation oncologist

    British Journal of Radiology, Vol. 89, Núm. 1067

  3. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy

    Journal of Contemporary Brachytherapy, Vol. 8, Núm. 6, pp. 477-483

2015

  1. Incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: Multicenter prospective observational study

    BMC Palliative Care, Vol. 14, Núm. 1

2014

  1. A prospective analysis of factors that influence weight loss in patients undergoing radiotherapy

    Chinese Journal of Cancer, Vol. 33, Núm. 4, pp. 204-210

  2. A prospective analysis of inter- and intrafractional errors to calculate CTV to PTV margins in head and neck patients

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 113-120

  3. Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy

    Journal of Contemporary Brachytherapy, Vol. 6, Núm. 2, pp. 154-160